Swiss Life Sciences Stock News

European markets have recently shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.70%, supported by firm risk appetite and stable earnings despite ongoing geopolitical volatility. As investors navigate these conditions, identifying stocks that are potentially undervalued compared to their intrinsic worth can offer opportunities for those looking to capitalize on market inefficiencies.

Clariant (SWX:CLN) has drawn fresh attention after reporting half year 2026 earnings that combined lower sales with higher profitability, including stronger net income and earnings per share from continuing operations. See our latest analysis for Clariant. The latest half year earnings and the favorable court ruling at the end of July appear to have supported sentiment around Clariant, with the CHF10.10 share price reflecting a 35.39% 1 month share price return and a 41.95% year to date share...

Why OC Oerlikon Stock Is Back on Investors’ Radar OC Oerlikon (SWX:OERL) is drawing fresh attention after reporting half year 2026 results that show a move from a net loss to net income of CHF 325 million, with earnings per share turning positive. See our latest analysis for OC Oerlikon. OC Oerlikon’s latest half year earnings release on 6 August 2026, which showed a shift to net income, has coincided with a 12.11% 30 day share price return and a 48.37% year to date share price return. The 1...

Sandoz Group (SWX:SDZ) is in focus after its half year 2026 results showed sales of US$5,761 million compared with US$5,232 million a year earlier, while net income and earnings per share were materially lower. See our latest analysis for Sandoz Group. The mixed half year earnings update appears to be a key backdrop for Sandoz Group’s recent price strength, with the share price at CHF72.78 and a 1 day share price return of 5.20%. That sits within a strong run, with momentum building as the 7...

Kardex Holding (SWX:KARN) drew investor attention after issuing 2026 guidance that targets revenue growth of 15% to 20% and an EBIT margin between 8% and 10%, sharpening expectations around profitability. See our latest analysis for Kardex Holding. Over the past year, Kardex Holding has seen the share price fall year to date and over 90 days, while the 1 year total shareholder return declined 23.43%. However, the 3 year total shareholder return of 31.52% points to a stronger longer term...

Novartis (SWX:NOVN) is back in focus after the US FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, materially widening the therapy’s eligible patient pool. See our latest analysis for Novartis. Against this backdrop, Novartis shares trade at CHF125.98, with a 90 day share price return of 10.8% and a year to date share price return of 16.11%. The 1 year total shareholder return of 38.01% points to...

Half year earnings highlight mixed trends for Interroll Holding stock Interroll Holding (SWX:INRN) reported half year 2026 earnings with sales of CHF 269.93 million compared with CHF 247.65 million a year earlier, while net income moved to CHF 19.75 million from CHF 21.22 million. See our latest analysis for Interroll Holding. Interroll Holding's recent earnings update comes after a period where the share price has risen about 10.17% over the past month but is still down 36.59% year to date,...

Shareholders might have noticed that Amrize AG ( VTX:AMRZ ) filed its second-quarter result this time last week. The...

Guidance and half-year results put Comet Holding stock in focus Comet Holding (SWX:COTN) has drawn investor attention after issuing new earnings guidance for 2026 and reporting half year results that show higher sales, net income and earnings per share compared with a year earlier. See our latest analysis for Comet Holding. The updated 2026 guidance and stronger half year figures have come after a sharp re rating in Comet Holding, with the share price up 50.45% year to date and a 1 year total...

Investors in Swiss Re AG ( VTX:SREN ) had a good week, as its shares rose 2.7% to close at CHF139 following the release...

The market came into Mobimo Holding’s H1 2026 release already on the back foot, with the stock down over the past week, month and quarter, and sitting at CHF342.50 at yesterday’s close. Yet the headline numbers tell a more nuanced story. Reported net profit margins over the last year sit near 60%, flattered by a one off gain of CHF132.6m, while debt coverage by operating cash flow looks weak. Today's price reaction reflects that tension. Are investors correctly pricing a stretched balance...

Why Swisscom’s latest earnings are drawing investor attention Swisscom (SWX:SCMN) reported half year 2026 earnings on 6 August, with sales of CHF 7,221 million compared to CHF 7,446 million a year earlier. Net income and earnings per share both moved higher. See our latest analysis for Swisscom. Swisscom’s recent half year earnings, which showed higher net income and earnings per share alongside lower sales, come after a mixed share price pattern where the share price is up 8.64% year to date...

Idorsia Ltd recently reported half-year 2026 results showing revenue of CHF 110.25 million, a shift from net income to a net loss, while reaffirming full-year sales guidance of CHF 200 million. At the same time, Idorsia entered an exclusive agreement with Jamjoom Pharmaceuticals to distribute and commercialize its insomnia treatment QUVIVIQ across Saudi Arabia and the Levant, adding a new regional partner and revenue stream structure built on upfront, milestone, and royalty payments. Next,...

Medacta Group revenue update and why it matters for investors Medacta Group (SWX:MOVE) reported unaudited first half 2026 revenue of €368 million, compared with €344 million a year earlier. This fresh trading statement is drawing attention to how the stock’s recent performance lines up with its underlying business trends. See our latest analysis for Medacta Group. Despite the latest revenue update, Medacta Group’s share price has weakened over 2026, with a year to date share price return of...

In August 2026, ams-OSRAM reported second-quarter results showing sales of €805 million alongside a net loss of €122 million, and issued guidance for third-quarter revenues between €770 million and €870 million while signalling slightly lower full-year 2026 revenue due to divestments and foreign exchange effects. An important implication is that modest year-on-year revenue softening is driven not only by operating conditions but also by portfolio reshaping and currency headwinds, which...

Why ABB Stock Is In Focus After The LevelTen Energy Deal ABB (SWX:ABBN) has put its energy and carbon advisory business in the spotlight after announcing a partnership and minority investment in LevelTen Energy, the clean energy marketplace and software platform. See our latest analysis for ABB. ABB shares trade at CHF81.76 after easing 0.68% on the day, while the share price return since the start of the year is up 33.51% and the 5 year total shareholder return of 176.72% points to strong...

Amrize stock has been grinding lower for weeks, down about 7% over the past three months. Yet Q2 landed with the kind of earnings snap that makes short term price action look impatient. The company delivered basic earnings per share of US$0.87 on revenue of US$3.5b, a clean rebound from the loss in Q1. That profit swing is now feeding into a bigger question for you as a shareholder: Is this the start of a more durable earnings run that eventually forces the market to reassess Amrize’s...

GAM Holding’s stock has been grinding higher in recent weeks, with the share price at CHF0.0828 after a strong 7 day and 30 day run. The quick win on the screen is only half the story. The fresh H1 2026 numbers highlight why this is still a high risk turnaround. The headline is the continuing earnings strain. GAM reported a loss of CHF58.2 million over the trailing twelve months on revenue of CHF48.8 million. The market sees a low P/S multiple and recent price momentum, but the key question...

Zurich Insurance Group shares came into these results slightly on the back foot after a modest slide over the past week, yet the latest half year numbers tell a more upbeat story. Business operating profit reached about US$4.8b and core earnings per share rose in the low double digits. Every major business line contributed, which matters far more to the long term thesis than a soft recent chart. The key tension for you as an investor is simple. The stock price is hesitating while the earnings...

The market has been steadily warming to Adecco Group in recent weeks, with the stock up about 46% over the past month. Today’s earnings, however, offer a cooler reality check. Revenue for the quarter sits at €5,997m, while basic earnings per share come in at €0.27, both solid but not especially rapid for a staffing heavyweight. The key issue is the tension between valuation and relatively thin profitability. Adecco trades on a trailing P/E of 15x and carries a net profit margin of 1.3%. The...

OC Oerlikon stock comes into this earnings day on a tear, up about 36% over the past three months, which sets a high bar for any result. The headline this time is not about eye catching revenue growth; it is about margins. Operational EBITDA of CHF 156m in the first half with a 19.7% margin and a 300 basis point expansion has turned the spotlight onto profitability rather than top line noise. The question now is whether that margin story fully justifies the recent re rating or whether short...

Galenica just served up earnings that look stronger than the recent share price would suggest. The stock closed at CHF82.2 on 7 August, with the past month and quarter both in slightly negative territory. Yet underneath that soft chart sits a healthcare retailer and distributor that reported H1 2026 sales of CHF2.143b and an adjusted earnings before interest and taxes margin in its Products & Care arm that edged higher. For a company often viewed as a dependable Swiss healthcare utility, the...

Swisscom stock heads into this earnings reaction priced for caution rather than excitement. The share price is roughly flat over the past week and month, and it has slipped about 6% over the last quarter, even as the company trades on a relatively rich trailing P/E of 24.8x. The headline from this quarter is not revenue movement. It is the profit squeeze. Net margin on a trailing basis now sits at 8.9%, lower than 10.2% a year earlier, even as management leans on Italian synergies and Swiss...

Swiss Re stock closed at CHF138.50, capping a solid 90 day run that left holders already sitting on a double digit gain before these results hit the tape. The headline today is simple. The market is reacting to a reinsurer that has already booked US$2.8b in net income for the first half of 2026 and a 23% return on equity. For short term traders, the question is how much of that strength is already priced in. For long term investors, the focus shifts to what those earnings and margins say...